Dual-action: targets GLP-1 + GIP receptors May produce greater weight loss results Stronger appetite suppression reported Significantly reduces "food noise" Supports blood sugar + metabolic health Best For Patients wanting maximum appetite control Those who plateaued on semaglutide Aggressive weight loss goals Single-action: targets GLP-1 receptors Proven, consistent weight loss results Supports appetite control Slows digestion for lasting fullness Well-established safety profile Best For First-time GLP-1 users Moderate weight loss goals Steady, predictable approach Not sure which is right for you
Semaglutide, under the brand name Wegovy, has been on the market after FDA approved it in 2021 for some adults who are obese or overweight
6 A large meta-analysis of randomised controlled trials published in 2024 found no significant association between GLP-1 medications and psychiatric disorders overall, but the authors noted that ongoing monitoring is advisable
Paxlovid Available Dosage Forms: Tablet Frequently asked questions More about nirmatrelvir / ritonavir Check interactions Compare alternatives Reviews (553) Side effects Dosage information During pregnancy Drug class: antiviral combinations En espaol Patient resources Other brands Professional resources Other brands Related treatment guides Further information Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Establish a protocol and stick to it
2021;184(10):2715-2732.e23
.jpg)
